Novartis AG (NVS): Price and Financial Metrics
Novartis AG (NVS)
Today's Latest Price: $92.90 USD
Updated Jan 27 4:00pm
Add NVS to WatchlistSign Up
POWR Components:
Trade Grade Buy & Hold Grade Peer Grade Industry Rank
Industry Rank:
Ranked of 240 in Medical - Pharmaceuticals
See all "A" rated Strong Buy stocks
NVS Stock Summary
- NVS has a market capitalization of $217,304,914,339 -- more than approximately 99.39% of US stocks.
- In terms of volatility of its share price, NVS is more volatile than merely 1.15% of stocks we're observing.
- Novartis Ag's shareholder yield -- a measure of how much capital is returned to stockholders via dividends and buybacks -- is 7.79%, greater than the shareholder yield of 80.14% of stocks in our set.
- If you're looking for stocks that are quantitatively similar to Novartis Ag, a group of peers worth examining would be PFE, MRK, LLY, ABT, and T.
- NVS's SEC filings can be seen here. And to visit Novartis Ag's official web site, go to www.novartis.com.
NVS Stock Price Chart Interactive Chart >
NVS Price/Volume Stats
| Current price | $92.90 | 52-week high | $99.84 |
| Prev. close | $95.94 | 52-week low | $69.18 |
| Day low | $92.86 | Volume | 5,090,479 |
| Day high | $94.87 | Avg. volume | 2,271,571 |
| 50-day MA | $91.71 | Dividend yield | 2.1% |
| 200-day MA | $87.59 | Market Cap | 212.62B |
Novartis AG (NVS) Company Bio
Novartis AG offers patented prescription medicines in various therapeutic areas, such as oncology, cardio-metabolic, immunology and dermatology, retina, respiratory, neuroscience, and established medicines. The company was founded in 1895 and is based in Basel, Switzerland.
NVS Price Forecast Based on DCF Valuation
| Current Price | DCF Fair Value Target: | Forecasted Gain: |
| $92.90 | $64.51 | -33% |
Below please find a table outlining a discounted cash flow forecast for NVS, in which we model out valuation assuming a variety of terminal growth rates. To summarize, we found that Novartis Ag ranked in the 42th percentile in terms of potential gain offered. Our DCF analysis suggests the stock is overvalued by about 32.33%. The most interesting components of our discounted cash flow analysis for Novartis Ag ended up being:
- NVS's estimated cost of debt, based largely on its market capitalization and its interest coverage ratio, is 3%; for context, that number is higher than 29.51% of tickers in our DCF set.
- The weighted average cost of capital for the company is 8. This value is greater than merely 24.31% stocks in the Healthcare sector that generate free cash flow.
| Terminal Growth Rate in Free Cash Flow | Return Relative to Current Share Price |
| 0% | -34% |
| 1% | -33% |
| 2% | -33% |
| 3% | -32% |
| 4% | -31% |
| 5% | -31% |
Want more companies with a valuation profile/forecast similar to that of Novartis Ag? See AMGN, QDEL, STE, MEDP, and USPH.
Loading social stream, please wait...